Home
/
AVANOS MEDICAL, INC.
/
Financials
/
Quarterly
AVANOS MEDICAL, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that AVANOS MEDICAL, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$177.80M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$175.00M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$167.50M
May 6, 2025
Q3
2025
Sep 30, 2024
$170.40M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$171.70M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$166.10M
May 6, 2025
Q3
2024
Sep 30, 2023
$171.30M
Oct 30, 2024
Q2
2024
Jun 30, 2023
$169.40M
Jul 31, 2024
Q1
2024
Mar 31, 2023
$159.30M
May 2, 2024
Q3
2023
Sep 30, 2022
$172.30M
Nov 1, 2023
Q2
2023
Jun 30, 2022
$170.90M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$197.40M
May 3, 2023
Q3
2022
Sep 30, 2021
$184.10M
Nov 2, 2022
Q2
2022
Jun 30, 2021
$186.40M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$180.70M
May 4, 2022
Q3
2021
Sep 30, 2020
$185.70M
Nov 2, 2021
Q2
2021
Jun 30, 2020
$163.70M
Aug 3, 2021
Q1
2021
Mar 31, 2020
$180.40M
May 7, 2021
Q3
2020
Sep 30, 2019
$171.40M
Nov 3, 2020
Q2
2020
Jun 30, 2019
$172.20M
Aug 4, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$156.40M
May 2, 2018
Q3
2017
Sep 30, 2017
$401.40M
Nov 1, 2017
Q2
2017
Jun 30, 2017
$399.20M
Aug 2, 2017
Q1
2018
Mar 31, 2017
$145.70M
May 2, 2018
Q3
2017
Sep 30, 2016
$397.50M
Nov 1, 2017
Q2
2017
Jun 30, 2016
$400.00M
Aug 2, 2017
Q1
2016
Mar 31, 2016
$384.80M
May 2, 2017
Q3
2016
Sep 30, 2015
$389.50M
Nov 3, 2016
Q2
2016
Jun 30, 2015
$389.30M
Aug 5, 2016
Q1
2016
Mar 31, 2015
$394.20M
May 9, 2016
Q3
2015
Sep 30, 2014
$408.50M
Nov 4, 2015
Q2
2015
Jun 30, 2014
$413.50M
Aug 12, 2015
Q1
2015
Mar 31, 2014
$410.70M
May 5, 2015
Q3
2014
Sep 30, 2013
$419.50M
Nov 20, 2014
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.40M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($76.80M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
$6.60M
May 6, 2025
Q3
2025
Sep 30, 2024
$4.30M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$1.80M
Aug 5, 2025
Q1
2025
Mar 31, 2024
($900.0K)
May 6, 2025
Q3
2024
Sep 30, 2023
($3.70M)
Oct 30, 2024
Q2
2024
Jun 30, 2023
($68.10M)
Jul 31, 2024
Q1
2024
Mar 31, 2023
($500.0K)
May 2, 2024
Q3
2023
Sep 30, 2022
$15.70M
Nov 1, 2023
Q2
2023
Jun 30, 2022
$12.50M
Aug 9, 2023
Q3
2022
Jun 30, 2022
$12.50M
Nov 2, 2022
Q3
2022
Mar 31, 2022
$5.40M
Nov 2, 2022
Q1
2023
Mar 31, 2022
$5.40M
May 3, 2023
Q3
2022
Sep 30, 2021
($35.30M)
Nov 2, 2022
Q3
2022
Jun 30, 2021
$38.50M
Nov 2, 2022
Q2
2022
Jun 30, 2021
$37.90M
Aug 9, 2022
Q1
2022
Mar 31, 2021
($7.60M)
May 4, 2022
Q3
2022
Mar 31, 2021
($8.40M)
Nov 2, 2022
Q3
2021
Sep 30, 2020
$19.30M
Nov 2, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$100.0K
Nov 5, 2025
Q2
2025
Jun 30, 2025
($74.50M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
$10.30M
May 6, 2025
Q3
2025
Sep 30, 2024
$12.00M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$6.30M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$4.00M
May 6, 2025
Q3
2024
Sep 30, 2023
$1.20M
Oct 30, 2024
Q2
2024
Jun 30, 2023
($2.10M)
Jul 31, 2024
Q1
2024
Mar 31, 2023
($6.10M)
May 2, 2024
Q3
2023
Sep 30, 2022
$12.80M
Nov 1, 2023
Q2
2023
Jun 30, 2022
$10.10M
Aug 9, 2023
Q1
2023
Mar 31, 2022
$8.60M
May 3, 2023
Q3
2022
Sep 30, 2021
$3.40M
Nov 2, 2022
Q2
2022
Jun 30, 2021
($7.30M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($12.40M)
May 4, 2022
Q3
2021
Sep 30, 2020
($100.0K)
Nov 2, 2021
Q2
2021
Jun 30, 2020
($1.80M)
Aug 3, 2021
Q1
2021
Mar 31, 2020
$600.0K
May 7, 2021
Q3
2020
Sep 30, 2019
($18.10M)
Nov 3, 2020
Q2
2020
Jun 30, 2019
($9.80M)
Aug 4, 2020